Search: onr:"swepub:oai:lup.lub.lu.se:464e5a23-ff9d-4bf8-861d-254597834e08" > Treatment response ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 05415naa a2200433 4500 | |
001 | oai:lup.lub.lu.se:464e5a23-ff9d-4bf8-861d-254597834e08 | |
003 | SwePub | |
008 | 160401s2008 | |||||||||||000 ||eng| | |
024 | 7 | a https://lup.lub.lu.se/record/10414432 URI |
024 | 7 | a https://doi.org/10.1093/rheumatology/ken0342 DOI |
040 | a (SwePub)lu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a art2 swepub-publicationtype |
072 | 7 | a ref2 swepub-contenttype |
100 | 1 | a Karlsson, JAu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)med-jnk |
245 | 1 0 | a Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. |
264 | c 2007-12-18 | |
264 | 1 | b Oxford University Press (OUP),c 2008 |
520 | a Objectives. To study treatment response rates of RA patients undergoing second- and third-line anti-TNF therapy and to identify baseline predictors of response to second-line treatment. Methods. RA patients monitored in a prospective, observational study, having switched anti-TNF therapy once (first-time switchers, n = 337) or twice (second-time switchers, n = 36)-i.e. following failures with one antibody- and one receptor-type agent-between March 1999 and December 2006, were studied. Treatment responses at 3 months were assessed by the ACR and European League Against Rheumatism (EULAR) response criteria. Predictive potentials for response to second-line treatment of demographics, baseline disease activity measures, disease and treatment characteristics were analysed using logistic regression. Results. ACR20 response was met by 51% of first-time and 35% of second-time switchers. Corresponding ACR50 rates were 27 and 18%; EULAR overall rates (EULAR good or moderate response) 71 and 58%; EULAR good rates 25 and 9% and 28-joint disease activity score (DAS28) remission rates 16 and 6%. Identified baseline predictors of response to second-line treatment were lower age and HAQ scores, elevated DAS28 values and having ceased the former anti-TNF treatment due to adverse events rather than inefficacy. No variable was predictive for all examined response criteria. Conclusions. Response rates of first-time anti-TNF switchers are somewhat below those of anti-TNF naïve RA patients, while the markedly inferior response rates of second-time switchers suggest other therapeutic options to be considered in this situation. Identified baseline predictors of response may be useful indicators to second-line anti-TNF therapy, but vary depending on the response criteria set studied. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Reumatologi och inflammation0 (SwePub)302102 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Rheumatology and Autoimmunity0 (SwePub)302102 hsv//eng |
653 | a RA | |
653 | a Anti-TNF | |
653 | a Switching | |
653 | a Predictors | |
653 | a Observational study | |
700 | 1 | a Kristensen, Lars Eriku Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-lkr |
700 | 1 | a C Kapetanovic, Melihau Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund Arthritis Research Group (LARG),Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups4 aut0 (Swepub:lu)reum-mcr |
700 | 1 | a Gülfe, Andersu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)med-agf |
700 | 1 | a Saxne, Toreu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)reum-tsa |
700 | 1 | a Geborek, Pierreu Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine4 aut0 (Swepub:lu)reum-pge |
710 | 2 | a Reumatologi och molekylär skelettbiologib Sektion III4 org |
773 | 0 | t Rheumatologyd : Oxford University Press (OUP)g 47:4, s. 507-513q 47:4<507-513x 1462-0332x 1462-0324 |
856 | 4 | u http://www.ncbi.nlm.nih.gov/pubmed/18304941?dopt=Abstractx freey FULLTEXT |
856 | 4 | u http://dx.doi.org/10.1093/rheumatology/ken034x freey FULLTEXT |
856 | 4 | u https://academic.oup.com/rheumatology/article-pdf/47/4/507/5067088/ken034.pdf |
856 | 4 8 | u https://lup.lub.lu.se/record/1041443 |
856 | 4 8 | u https://doi.org/10.1093/rheumatology/ken034 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Copy and save the link in order to return to this view